Sentynl Therapeutics, Inc. Email Format

Pharmaceutical ManufacturingCalifornia, United States11-50 Employees

Sentynl Therapeutics, Inc. is a pharmaceutical manufacturing company based at 420 Stevens Avenue, Suite 200, Solana Beach, California 92075, United States, and operates as a wholly owned subsidiary of Zydus Lifesciences Ltd. It is a commercial stage biopharmaceutical company focused on developing therapies for patients with rare diseases. The company is advancing Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome, with an agreement to collaborate with PRG S&T to accelerate its clinical development and an FDA orphan drug designation for the therapy; it is also developing CUTX-101 (Copper Histidinate) for Menkes disease, with the FDA acceptance of its NDA for priority review. In 2024, Sentynl acquired Zokinvy (lonafarnib) and the company Eigerbio, expanding its product portfolio. The organization employs 11-50 people and earned Great Place To Work certification in 2024.

Sign up for free to view info

Company overview Employee directory